Developer docs
API playgroundTry for free, no card

Search company profiles

Ixaka

Full company profile

uuid0002jxg

Namestring
Ixaka
Websiteurl
ixaka.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Ixaka is a privately held cell and gene therapy company founded in 2015 and headquartered in London, United Kingdom. The company is focused on developing therapies that leverage the body's natural capacity to cure disease, operating in the regenerative medicine space across two disclosed therapeutic indications: Critical Limb Ischemia (CLI), a severe form of peripheral artery disease, and Acute Pancreatitis, an inflammatory condition of the pancreas. These indications represent markets valued at $1,845M and $722M respectively in 2023 across the 7MM (United States, EU4, UK, and Japan), according to third-party market research referenced in the source data.

The company operates with a workforce of 51–100 employees and a full executive leadership team spanning CEO, Chairman, Vice Chairman, and functional CXO roles including Chief Medical, Scientific, Financial, Information, and Manufacturing Officers, alongside a regional Managing Director for Iberia. This organizational structure is consistent with a clinical-stage biotech advancing toward later-stage trials and commercial supply readiness. The underlying technology platform is cell-based, built around the principle of mobilizing endogenous repair mechanisms, though specific platform architecture and clinical-stage asset details are not disclosed in the available source material.

Ixaka's business model is currently pre-commercial. Revenue mechanics are not disclosed, and no pricing model, product launches, or customer relationships are reported in the source data. The company has been capitalized through approximately $72.7M in cumulative funding across five rounds between 2015 and 2021, with primary backer ZenPharma Limited leading the largest rounds and Innovate UK providing non-dilutive grant funding. As a clinical-stage biotech, the company's value-creation path runs through clinical trial progression, regulatory milestones, and eventual commercialization or partnership/out-licensing of its therapeutic candidates.

Short descriptiontext

Ixaka is a London-based, privately held cell and gene therapy company founded in 2015 that develops regenerative cell-based treatments targeting Critical Limb Ischemia and Acute Pancreatitis, serving patients with severe vascular and inflammatory conditions where current therapeutic options are limited.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cell and gene therapy, regenerative medicine, cell therapy platform, critical limb ischemia treatment, acute pancreatitis therapy
Industry3 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell and Gene Therapy / Regenerative Medicine
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ixaka develops proprietary cell and gene therapies aimed at leveraging the body's natural ability to cure disease, with a focus on regenerative treatments for vascular and inflammatory conditions. Its pipeline targets Critical Limb Ischemia and Acute Pancreatitis, indications where current therapeutic options are limited and unmet medical need is high.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Cell Therapy for Critical Limb Ischemia
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

DelveInsight published a market research report on Critical Limb Ischemia that references Ixaka as one of the companies operating in this therapeutic space. The market report valued the CLI market at USD 1,845 million in 2023 with projections for significant growth through 2034 driven by increasing disease prevalence and a rich pipeline of emerging therapies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing autologous stem cell treatments for Critical Limb Ischemia; directly named alongside Ixaka in the CLI competitive landscape.

2Caladrius Biosciences
TypeDirect peer
Description

Cell therapy company with programs in ischemic conditions including CLI; operates in the same regenerative medicine space as Ixaka.

TypeDirect peer
Description

Commercial-stage cell therapy company listed as a competitor in the CLI market; serves as a benchmark for Ixaka's potential commercial trajectory.

TypeDirect peer
Description

Gene and cell therapy company referenced alongside Ixaka in the CLI therapeutic space; comparable in stage and modality.

TypeDirect peer
Description

Commercial-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and cardiovascular conditions; directly comparable platform technology.

6Athersys
TypeDirect peer
Description

Clinical-stage cell therapy company developing MultiStem for ischemic and inflammatory conditions including CLI; closely comparable target indications.

7Pluristem Therapeutics
TypeDirect peer
Description

Cell therapy company using placenta-derived stem cells for peripheral artery disease and CLI; direct comparator in the vascular regenerative space.

TypeBroad incumbent
Description

Large medical products company with cell therapy and regenerative medicine interests in CLI; provides scale and distribution capabilities that Ixaka lacks.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic cell transplants for vascular and neurological conditions; similar platform approach and stage.

TypeEmerging player
Description

Cell therapy company historically developing adipose-derived regenerative cells for CLI; relevant historical comparator in the same indication.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ixaka

Cell and Gene Therapy / Regenerative Medicineixaka.com

Ixaka is a London-based, privately held cell and gene therapy company founded in 2015 that develops regenerative cell-based treatments targeting Critical Limb Ischemia and Acute Pancreatitis, serving patients with severe vascular and inflammatory conditions where current therapeutic options are limited.

What Ixaka does

Ixaka is a privately held cell and gene therapy company founded in 2015 and headquartered in London, United Kingdom. The company is focused on developing therapies that leverage the body's natural capacity to cure disease, operating in the regenerative medicine space across two disclosed therapeutic indications: Critical Limb Ischemia (CLI), a severe form of peripheral artery disease, and Acute Pancreatitis, an inflammatory condition of the pancreas. These indications represent markets valued at $1,845M and $722M respectively in 2023 across the 7MM (United States, EU4, UK, and Japan), according to third-party market research referenced in the source data.

The company operates with a workforce of 51–100 employees and a full executive leadership team spanning CEO, Chairman, Vice Chairman, and functional CXO roles including Chief Medical, Scientific, Financial, Information, and Manufacturing Officers, alongside a regional Managing Director for Iberia. This organizational structure is consistent with a clinical-stage biotech advancing toward later-stage trials and commercial supply readiness. The underlying technology platform is cell-based, built around the principle of mobilizing endogenous repair mechanisms, though specific platform architecture and clinical-stage asset details are not disclosed in the available source material.

Ixaka's business model is currently pre-commercial. Revenue mechanics are not disclosed, and no pricing model, product launches, or customer relationships are reported in the source data. The company has been capitalized through approximately $72.7M in cumulative funding across five rounds between 2015 and 2021, with primary backer ZenPharma Limited leading the largest rounds and Innovate UK providing non-dilutive grant funding. As a clinical-stage biotech, the company's value-creation path runs through clinical trial progression, regulatory milestones, and eventual commercialization or partnership/out-licensing of its therapeutic candidates.

Ixaka firmographics

Firmographics
Name
Ixaka
Website
https://ixaka.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Ixaka is a London-based, privately held cell and gene therapy company founded in 2015 that develops regenerative cell-based treatments targeting Critical Limb Ischemia and Acute Pancreatitis, serving patients with severe vascular and inflammatory conditions where current therapeutic options are limited.
Ownership category
akta.pro rank

Ixaka industry classification

Industry
Product category
Cell and Gene Therapy / Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell and gene therapy
  • Regenerative medicine
  • Cell therapy platform
  • Critical limb ischemia treatment
  • Acute pancreatitis therapy

Where Ixaka is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Ixaka business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Ixaka product offering

Product offering

Core offering

Ixaka develops proprietary cell and gene therapies aimed at leveraging the body's natural ability to cure disease, with a focus on regenerative treatments for vascular and inflammatory conditions. Its pipeline targets Critical Limb Ischemia and Acute Pancreatitis, indications where current therapeutic options are limited and unmet medical need is high.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell Therapy for Critical Limb Ischemia

Companies that use Ixaka

Customer profile

Segments2 records

Ideal customer profiles2 records

Ixaka technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Ixaka partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • DelveInsightminorOthersDelveInsight published a market research report on Critical Limb Ischemia that references Ixaka as one of the companies operating in this therapeutic space. The market report valued the CLI market at USD 1,845 million in 2023 with projections for significant growth through 2034 driven by increasing disease prevalence and a rich pipeline of emerging therapies.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Ixaka competitors and assessment

Company assessment

Direct peers

  • Hemostemix: Clinical-stage cell therapy company developing autologous stem cell treatments for Critical Limb Ischemia; directly named alongside Ixaka in the CLI competitive landscape.
  • Caladrius Biosciences: Cell therapy company with programs in ischemic conditions including CLI; operates in the same regenerative medicine space as Ixaka.
  • Vericel Corporation: Commercial-stage cell therapy company listed as a competitor in the CLI market; serves as a benchmark for Ixaka's potential commercial trajectory.
  • Helixmith: Gene and cell therapy company referenced alongside Ixaka in the CLI therapeutic space; comparable in stage and modality.
  • Mesoblast: Commercial-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and cardiovascular conditions; directly comparable platform technology.
  • Athersys: Clinical-stage cell therapy company developing MultiStem for ischemic and inflammatory conditions including CLI; closely comparable target indications.
  • Pluristem Therapeutics: Cell therapy company using placenta-derived stem cells for peripheral artery disease and CLI; direct comparator in the vascular regenerative space.
  • Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplants for vascular and neurological conditions; similar platform approach and stage.

Broad incumbents

  • Baxter International: Large medical products company with cell therapy and regenerative medicine interests in CLI; provides scale and distribution capabilities that Ixaka lacks.

Emerging players

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Ixaka social profiles

Digital presence

Ixaka financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ixaka leadership team

Management profile

Number of profiles

Profiles9 records

Ixaka funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ixaka M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ixaka

What does Ixaka do?

Ixaka develops proprietary cell and gene therapies aimed at leveraging the body's natural ability to cure disease, with a focus on regenerative treatments for vascular and inflammatory conditions. Its pipeline targets Critical Limb Ischemia and Acute Pancreatitis, indications where current therapeutic options are limited and unmet medical need is high.

Is Ixaka a public or private company?

Ixaka is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ixaka founded?

Ixaka was founded in 2015. It employs 1 to 10 people.

Where is Ixaka based?

Ixaka is headquartered in London, United Kingdom, in the Europe region.

Who are Ixaka's main competitors?

Direct peers on record are Hemostemix, Caladrius Biosciences, Vericel Corporation, Helixmith, Mesoblast, Athersys, Pluristem Therapeutics and Lineage Cell Therapeutics. Baxter International is listed as a broad incumbent. Cytori Therapeutics (now Plus Therapeutics) is listed as an emerging player.

Does Ixaka have an API?

No public API is recorded for Ixaka.

What industry is Ixaka in?

Ixaka's product category is Cell and Gene Therapy / Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCritical Limb Ischemia Market: High-Growth Opportunities for Investors to 2034 - DelveInsight | Baxter, Ixaka, Hemostemix Inc., Caladrius Biosciences, Vericel Corporation, Helixmith, Lifecells, LLCDelveInsight published a market research report on Critical Limb Ischemia, valued at approximately USD 1,845 million in 2023, projecting significant growth through 2034 driven by increasing disease prevalence and a rich pipeline of emerging therapies.FinSMEsAlaya.bio Acquires Key Assets From Ixaka FranceAlaya.bio acquired all assets from Ixaka France, including a broad patent portfolio, preclinical data, exclusive licenses for polymeric nanoparticle technology, and laboratory facilities. This transaction accelerates Alaya.bio's in vivo gene delivery programs by providing proof of concept for anti-tumoral efficacy in immunocompetent mouse models.BioSpaceAlaya.bio Acquires Key Assets From Ixaka France, Accelerating the Progress of Its Novel In Vivo CAR-T Immunotherapy PlatformAlaya.bio has acquired all assets previously owned by Ixaka France, including a patent portfolio, preclinical data, and laboratory facilities. This transaction is intended to accelerate Alaya.bio's in vivo CAR-T immunotherapy platform by leveraging proof of concept for anti-tumoral efficacy in mouse models.Business Wire BlogAlaya.bio Acquires Key Assets From Ixaka France, Accelerating the Progress of Its Novel In Vivo CAR-T Immunotherapy PlatformAlaya.bio has acquired all assets from Ixaka France, including a robust patent portfolio, preclinical data, and viral vector bioproduction facilities, to accelerate its in vivo CAR-T immunotherapy platform. This strategic move provides Alaya.bio with proof of concept for anti-tumoral efficacy in mouse models and positions the company as a leader in in vivo gene delivery. The acquisition is intended to simplify the development and manufacturing processes of CAR-T cell therapies by eliminating costly external manufacturing steps.BioSpaceIxaka Appoints Karen Miller as Chief Scientific OfficerIxaka appointed Karen Miller as Chief Scientific Officer, bringing over 30 years of biotech and pharma experience. She previously led pipeline research at Adaptimmune and held roles at GSK. The appointment aims to support preclinical development of Ixaka's gene delivery products and REX-001.BioSpaceIxaka Expands Management Team with Multiple AppointmentsIxaka appointed Nick Robbins-Cherry as CFO and board director, and George O'Rourke as VP and GM of Ixaka France. Robbins-Cherry brings 30 years of finance experience, while O'Rourke previously led Novartis Gene Therapy's France operations. The appointments follow positive interim Phase 3 data for REX-001 and precede the clinic entry of CELTIC.The Pharma LetterBRIEF—Rexgenero reborn as IxakaIxaka, a cell and gene therapy company, was launched after Rexgenero's integration of its nanoparticle gene therapy business in France and shareholder restructuring. The company will develop concentrated multi-cell therapies and targeted nanoparticle therapeutics, with REX-001, an autologous cell-based product for chronic limb-threatening ischaemia, in a Phase III trial across Europe.The Pharma LetterRexgenero cleared to continue Phase III trial of REX-001Rexgenero's IDMC unanimously approved continuing its REX-001 Phase III trial for diabetic patients with critical limb-threatening ischemia after reviewing safety data from 22 subjects. The company's chief medical officer said the recommendation reflects the drug's safety profile and that recruitment is back on track despite pandemic challenges.FierceBiotechBritish cell therapy biotech Rexgenero nabs life science veteran as CMOGilbert Wagener, a life science veteran, joined Rexgenero as senior vice president and chief medical officer to lead cell therapy development. The company is advancing REX-001, a late-stage cell therapy for critical limb ischemia, with two phase 3 trials in the U.K. Wagener will also oversee regulatory strategy.The Pharma LetterRexgenero buys French Car-T cell specialist's assetsRexgenero acquired all key assets of Paris-based aratinga.bio, a pre-clinical-stage immunotherapy firm developing an off-the-shelf Car-T cell therapy. The company, founded in 2017, uses a novel approach for in vivo targeting and transduction of T cells.